Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Investor Presentation (December 2020)
15 slides from Alembic Pharmaceuticals's investor presentation, December 2020
Slide 1: Alembic Pharmaceuticals Limited Investor presentation – December 2020
Alembic Pharmaceuticals Limited Investor presentation – December 2020 BSE & NSE: APLLTD
Slide 2: Milestones
Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed 2012 Formed a JV, Rhizen, for NCE research Launched fir
Slide 3: Financial Highlights
Financial Highlights INR Bn Particulars Q3 FY21 Q3 FY20 Growth YTD FY21 YTD FY20 Growth YTD FY20 Net Sales 13.14 12.09 9% 41.13 33.99 21% 46.06 EBIDTA Pre R&D 5.36 4.66 15% 17.13 13.35 28% 18.15 Margin % 41% 39% 42% 39% 39% R&D 1.48 1.46 2% 4.75 4.60 3% 6.45 R&D % 11% 12% 12% 14% 14% EBIDTA Post R&D
Slide 4: Business snapshot – Q3FY21
Business snapshot – Q3FY21 Formulations Generics Branded API Total US Ex-US India Revenue Q3FY21 (INR Bn) 5.12 1.71 4.18 2.14 13.14 API Vet 16% 16% 4% 39% Generics Q3FY21 Revenue 52% Acute Contribution 11% Branded 32% 13% Speciality 17% Growth Q3FY21 -1% 14% 14% 21% 9% over Q3FY20 Growth Q3FY21 -12%
Slide 5: Business snapshot – YTDFY21
Business snapshot – YTDFY21 Formulations Generics Branded API Total US Ex-US India Revenue YTDFY21 (INR Bn) 16.89 5.44 11.38 7.41 41.13 API Vet 18% 18% 3% YTDFY21 Revenue Generics 41% 54% Contribution Acute 9% Branded Speciality 15% 28% 13% Growth YTDFY21 21% 49% 5% 34% 21% over YTDFY20 • Well-estab
Slide 6: US Generic
US Generic INR Bn Revenue – Q3 FY21 INR Bn Revenue – Last 4 Years CAGR - 29% 19.76 5.15 -1% i 5.12 12.88 9.19 9.20 Q3FY20 Q3FY21 FY17 FY18 FY19 FY20 Approved ANDAs Derma Injectable 1 13 ➢ Well-established US front end having strong customer base Ophthalmic 13 ➢ Expanded our capabilities to deliver a
Slide 7: Ex-US Generics
Ex-US Generics Revenue : Q3 FY21 INR Bn Revenue – Last 4 Years INR Bn CAGR - 16% 1.71 1.49 4.94 4.97 Q3FY20 Q3FY21 3.20 ➢ Ex-US driven by partnership 2.86 ➢ Presence in following markets - Europe, Canada, Australia, Brazil and South Africa ➢ The business will focus on new launches across key markets
Slide 8: API
API Revenue : Q3 FY21 INR Bn Revenue – Last 4 Years INR Bn CAGR - 3% 2.14 1.77 7.71 7.08 6.40 6.51 Q3FY20 Q3FY21 ➢ Sales across geographies as preferred supplier ➢ Investing in plants to create additional capacities ➢ FDA Compliant plants ➢ State of the art R&D center and Process development lab ➢ 1
Slide 9: R&D Significant investments in building capabilities
R&D Significant 10.0 investments in building capabilities INR Bn ANDA – Accelerated filings & approvals 37* 8.0 Filing 13.7% 14.0% 13.1% 12.7% 29 30 Approval 6.0 25 10.1% R&D Spend 20 19 18* * 11 Filings & 4.0 7 Approvals 6.5 R&D % of 10 were 5.0 sales 2.0 4.3 4.1 8 contributed by 3.2 5 acquisition
Slide 10: State of the art facilities and infrastructure
State of the art facilities and infrastructure Audit/Filing Location Dosage Form status International Generics F1 – Panelav General Oral Solids Mar’20* Oncology Oral Solids Jun’19* F2 – Panelav Oncology Injectables Q4FY21# F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic Jan’2
Slide 11: Branded Business
Branded Business Revenue – Q3 FY21 INR Bn Revenue – Last 4 Years CAGR - 4% INR Bn 4.18 14.3 3.68 13.8 0.50 12.5 12.7 0.37 Vet 1.43 1.37 Acute Speciality 2.25 1.93 Q3FY20 Q3FY21 FY17 FY18 FY19 FY20 Marketing organization Key achievements ➢ 5000 + Marketing team ➢ 3 Brands in top 300 ➢ 17 Marketing di
Slide 12: Therapy-wise Performance Q3 FY21
Therapy-wise Performance Q3 FY21 Q3 FY21 Q3 FY20 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy (%) Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 15 1.9 15 15 9 1.9 4 6 Gynecology 6 2.6 19 14
Slide 13: Therapy-wise Performance YTD FY21
Therapy-wise Performance YTD FY21 YTD FY21 YTD FY20 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy (%) Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 14 1.9 15 17 11 1.9 5 3 Gynecology -1 2.4 3
Slide 14: Financials : Generating consistent returns
Financials : Generating consistent returns Revenue INR Bn EBIDTA Net Profit INR Bn 46.06 INR Bn 12.13 39.35 8.29 31.34 31.31 8.75 5.84 6.15 6.42 4.03 4.13 FY17 FY18 FY19 FY20 FY17 FY18 FY19 FY20 FY17 FY18 FY19 FY20 CAGR - 14% CAGR - 25% CAGR - 27% EBIDTA margin % Capex ROCE % INR Bn 32* 26 6.97 30*
Slide 15: Thank you
Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu
Alembic Pharmaceuticals — Investor Presentation (December 2020) on 6ix